Biomarin Pharmaceutical Inc (BMRN) 100.76 $BMRN
Is This Company the Big Winner in Obama's Push for Precision Medicine?
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 14, 8:56AM CST
Source: Illumina Inc. President Obama has released more details about his plans to fund a precision medicine initiative that the administration hopes will mean that doctors can deliver the right medicine to the right patient at the right dose ...
JNJ: 99.62 (+1.18), BMRN: 100.76 (+1.98), AZN: 69.96 (+0.20), ILMN: 198.54 (+1.81), BMY: 60.04 (+0.56), SNY: 49.42 (+0.82)
Acorda Beats Q4 Earnings Estimates; Ampyra Sales Grow - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:26AM CST
Acorda Therapeutics's (ACOR) fourth quarter earnings of 33 cents per share surpassed the Zacks Consensus Estimate.
BIIB: 391.66 (-0.45), BMRN: 100.76 (+1.98), ACHN: 10.89 (-0.20), ACOR: 36.14 (-0.51)
Amgen's Skin Cancer Drug to Face FDA Advisory Panel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 3:10PM CST
Amgen's (AMGN) experimental skin cancer treatment, talimogene laherparepvec, is scheduled to face twin FDA advisory committees on Apr 29, 2015.
BMRN: 100.76 (+1.98), KITE: 62.59 (+0.82), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30)
Oncolytics' Reolysin Gets Orphan Status for Ovarian Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 11:40AM CST
Oncolytics Biotech Inc.'s (ONCY) lead candidate, Reolysin, has been granted orphan drug designation by the FDA for the treatment of ovarian cancer.
BIIB: 391.66 (-0.45), ONCY: 0.51 (+0.02), BMRN: 100.76 (+1.98)
Isis Pharma to Get $5M from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 1:42PM CST
Isis Pharmaceuticals (ISIS) to receive a milestone payment of $5 million from Biogen (BIIB).
JNJ: 99.62 (+1.18), BIIB: 391.66 (-0.45), BMRN: 100.76 (+1.98), ISIS: 63.86 (-0.43)
Synthetic Biologics Unveils Phase Ib Safety Data on SYN-004 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 12:30PM CST
Synthetic Biologics, Inc. (SYN) announced positive top-line results from phase Ib study on SYN-004.
SYN: 2.13 (+0.18), BMRN: 100.76 (+1.98), ALNY: 95.54 (+1.67)
Genomic Health Loss Narrower than Expected, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 9:06AM CST
Genomic Health (GHDX) delivered mixed financial numbers in fourth-quarter 2014 with bottom-line beat but revenue miss.
BMRN: 100.76 (+1.98), OPHT: 51.11 (+0.12), GHDX: 31.12 (+0.28), AFFX: 11.45 (+0.02)
Seattle Genetics Posts Narrower-than-Expected Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 8:18AM CST
Seattle Genetics, Inc. (SGEN) reported a loss of 22 cents per share, narrower than the Zacks Consensus Estimate of a loss of 27 cents.
BMRN: 100.76 (+1.98), SGEN: 31.57 (+0.36), BMY: 60.04 (+0.56)
Prosensa Announces Voluntary Delisting and Advance Liquidation Distribution
GlobeNewswire - Tue Feb 10, 11:16AM CST
Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company"
, the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced today that, on February 11, 2015, it will file a Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934 (the "Exchange Act" (the "Form 25" , with the Securities Exchange Commission ("SEC" in order to voluntarily delist the registered shares of the Company, nominal value EUR0.01 per share (the "Shares" from the NASDAQ Global Select Market ("NASDAQ" , which will become effective 10 days after filing. NASDAQ has advised the Company that it will suspend trading of the Shares after the market closes on February 11, 2015. As such, shareholders of the Company will not be able to trade their shares on NASDAQ thereafter.
BMRN: 100.76 (+1.98), RNA: 18.65 (unch)
Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea
at Investor's Business Daily - Tue Feb 10, 10:01AM CST
Regeneron Pharmaceuticals (REGN) reported weaker-than-expected fourth-quarter earnings Tuesday morning, but the large-cap biotech topped sales views and offered an upbeat outlook for its blockbuster Eylea eye drug, which generates well more than half...
CBPO: 69.12 (+0.42), BIIB: 391.66 (-0.45), INSY: 51.50 (-0.66), PCYC: 163.28 (+0.23), BMRN: 100.76 (+1.98), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), CELG: 115.88 (+0.16)
BioMarin Announces 2 Oral and 8 Poster Presentations at Lysosomal Disease Network's 11th Annual WORLD Symposium(TM)
GlobeNewswire - Mon Feb 09, 7:06AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the company would make two data presenations in addition to presenting eight posters at the Lysosomal Disease Network's 11 Annual WORLD Symposium(TM) from February 9-13 in Orlando, Florida.
BMRN: 100.76 (+1.98)
BioMarin to Attend Upcoming Investor Conferences
GlobeNewswire - Wed Feb 04, 7:01AM CST
- Leerink Global Healthcare Conference on February 12
BMRN: 100.76 (+1.98)
BioMarin reports February 25
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 8:15AM CST
BMRN: 100.76 (+1.98)
BioMarin to Host Fourth Quarter and Full Year 2014 Financial Results Conference Call and Webcast on Wednesday, February 25 at 4:30pm ET
GlobeNewswire - Tue Feb 03, 7:00AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 25, at 4:30pm ET to discuss fourth quarter and full-year 2014 financial results and provide a general business update.
BMRN: 100.76 (+1.98)
After Yesterday's Decline of 1.87%, BioMarin Pharmaceutical Offers Investors Better Value
Comtex SmarTrend(R) - Mon Feb 02, 4:54PM CST
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $93.87 to a high of $97.90. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $96.38 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMRN: 100.76 (+1.98)
3 Biotech Stocks to Buy in February
Motley Fool Staff - Motley Fool - Mon Feb 02, 9:01AM CST
When it comes to figuring out the best stocks to buy in any given month or year, crystal balls can be hazy, but our top Motley Fool contributors have scoured SEC filings, read industry trade journals, and crunched numbers to uncover three biotech...
FLML: 14.15 (+0.15), BMRN: 100.76 (+1.98), RNA: 18.65 (unch), CELG: 115.88 (+0.16)
An $8 Billion Hedge Fund Bought This Extremely Risky Stock: Should You?
George Budwell, The Motley Fool - Motley Fool - Sun Feb 01, 12:02PM CST
The market activity of billionaire investors tends to attract a lot of attention because these billionaires are often perceived as having some kind of special insight into the direction of the broader market or individual stocks. In the world of...
ACAD: 34.21 (+0.37), PCYC: 163.28 (+0.23), BMRN: 100.76 (+1.98), GEVA: 99.75 (-1.68)
Prosensa Announces Intent to Voluntarily Delist From NASDAQ
GlobeNewswire - Fri Jan 30, 7:36AM CST
Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company" , the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced today that it intends to voluntarily delist the registered shares of the Company, nominal value EUR0.01 per share (the "Shares" , from the NASDAQ Global Select Market ("NASDAQ" . Upon satisfaction of the applicable requirements for deregistration, Prosensa also intends to deregister the Shares under the Securities Exchange Act of 1934, as amended (the "Exchange Act" and to suspend its reporting obligations under the Exchange Act once it is eligible to do so.
BMRN: 100.76 (+1.98), RNA: 18.65 (unch)
BioMarin Announces Final Results of Tender Offer for Prosensa's Shares and Completion of Subsequent Offering Period
GlobeNewswire - Fri Jan 30, 7:00AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the final results of, and the completion of the subsequent offering period relating to, the previously announced tender offer by its subsidiaries, BioMarin Falcons B.V. and BioMarin Giants B.V. (together, "Purchaser" , to acquire all of the outstanding ordinary shares of Prosensa Holding N.V. (Nasdaq:RNA) at a purchase price of $17.75 per share, net to the seller in cash (the "Cash Consideration" , plus one non-transferrable contingent value right to receive cash payments of up to $4.14 per share in the aggregate upon the achievement of certain product approval milestones ("CVR" , in each case, without interest thereon and less any applicable withholding taxes.
BMRN: 100.76 (+1.98), RNA: 18.65 (unch)
Synageva Starts Dosing in Phase I/II Study for Sanfilippo B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 5:25PM CST
Synageva BioPharma Corp. (GEVA) has commenced patient dosing in a phase I/II study on SBC-103 for mucopolysaccharidosis IIIB (also known as Sanfilippo B syndrome).
BMRN: 100.76 (+1.98), GEVA: 99.75 (-1.68), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Is This Company the Big Winner in Obama's Push for Precision Medicine?
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 14, 8:56AM CST
Source: Illumina Inc. President Obama has released more details about his plans to fund a precision medicine initiative that the administration hopes will mean that doctors can deliver the right medicine to the right patient at the right dose ...
JNJ: 99.62 (+1.18), BMRN: 100.76 (+1.98), AZN: 69.96 (+0.20), ILMN: 198.54 (+1.81), BMY: 60.04 (+0.56), SNY: 49.42 (+0.82)
Acorda Beats Q4 Earnings Estimates; Ampyra Sales Grow - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:26AM CST
Acorda Therapeutics's (ACOR) fourth quarter earnings of 33 cents per share surpassed the Zacks Consensus Estimate.
BIIB: 391.66 (-0.45), BMRN: 100.76 (+1.98), ACHN: 10.89 (-0.20), ACOR: 36.14 (-0.51)
Amgen's Skin Cancer Drug to Face FDA Advisory Panel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 3:10PM CST
Amgen's (AMGN) experimental skin cancer treatment, talimogene laherparepvec, is scheduled to face twin FDA advisory committees on Apr 29, 2015.
BMRN: 100.76 (+1.98), KITE: 62.59 (+0.82), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30)
Oncolytics' Reolysin Gets Orphan Status for Ovarian Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 11:40AM CST
Oncolytics Biotech Inc.'s (ONCY) lead candidate, Reolysin, has been granted orphan drug designation by the FDA for the treatment of ovarian cancer.
BIIB: 391.66 (-0.45), ONCY: 0.51 (+0.02), BMRN: 100.76 (+1.98)
Isis Pharma to Get $5M from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 1:42PM CST
Isis Pharmaceuticals (ISIS) to receive a milestone payment of $5 million from Biogen (BIIB).
JNJ: 99.62 (+1.18), BIIB: 391.66 (-0.45), BMRN: 100.76 (+1.98), ISIS: 63.86 (-0.43)
Synthetic Biologics Unveils Phase Ib Safety Data on SYN-004 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 12:30PM CST
Synthetic Biologics, Inc. (SYN) announced positive top-line results from phase Ib study on SYN-004.
SYN: 2.13 (+0.18), BMRN: 100.76 (+1.98), ALNY: 95.54 (+1.67)
Genomic Health Loss Narrower than Expected, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 9:06AM CST
Genomic Health (GHDX) delivered mixed financial numbers in fourth-quarter 2014 with bottom-line beat but revenue miss.
BMRN: 100.76 (+1.98), OPHT: 51.11 (+0.12), GHDX: 31.12 (+0.28), AFFX: 11.45 (+0.02)
Seattle Genetics Posts Narrower-than-Expected Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 8:18AM CST
Seattle Genetics, Inc. (SGEN) reported a loss of 22 cents per share, narrower than the Zacks Consensus Estimate of a loss of 27 cents.
BMRN: 100.76 (+1.98), SGEN: 31.57 (+0.36), BMY: 60.04 (+0.56)
Prosensa Announces Voluntary Delisting and Advance Liquidation Distribution
GlobeNewswire - Tue Feb 10, 11:16AM CST
Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company"
, the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced today that, on February 11, 2015, it will file a Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934 (the "Exchange Act" (the "Form 25" , with the Securities Exchange Commission ("SEC" in order to voluntarily delist the registered shares of the Company, nominal value EUR0.01 per share (the "Shares" from the NASDAQ Global Select Market ("NASDAQ" , which will become effective 10 days after filing. NASDAQ has advised the Company that it will suspend trading of the Shares after the market closes on February 11, 2015. As such, shareholders of the Company will not be able to trade their shares on NASDAQ thereafter. BMRN: 100.76 (+1.98), RNA: 18.65 (unch)
Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea
at Investor's Business Daily - Tue Feb 10, 10:01AM CST
Regeneron Pharmaceuticals (REGN) reported weaker-than-expected fourth-quarter earnings Tuesday morning, but the large-cap biotech topped sales views and offered an upbeat outlook for its blockbuster Eylea eye drug, which generates well more than half...
CBPO: 69.12 (+0.42), BIIB: 391.66 (-0.45), INSY: 51.50 (-0.66), PCYC: 163.28 (+0.23), BMRN: 100.76 (+1.98), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), CELG: 115.88 (+0.16)
BioMarin Announces 2 Oral and 8 Poster Presentations at Lysosomal Disease Network's 11th Annual WORLD Symposium(TM)
GlobeNewswire - Mon Feb 09, 7:06AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the company would make two data presenations in addition to presenting eight posters at the Lysosomal Disease Network's 11 Annual WORLD Symposium(TM) from February 9-13 in Orlando, Florida.
BMRN: 100.76 (+1.98)
BioMarin to Attend Upcoming Investor Conferences
GlobeNewswire - Wed Feb 04, 7:01AM CST
- Leerink Global Healthcare Conference on February 12
BMRN: 100.76 (+1.98)
BioMarin reports February 25
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 8:15AM CST
BMRN: 100.76 (+1.98)
BioMarin to Host Fourth Quarter and Full Year 2014 Financial Results Conference Call and Webcast on Wednesday, February 25 at 4:30pm ET
GlobeNewswire - Tue Feb 03, 7:00AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 25, at 4:30pm ET to discuss fourth quarter and full-year 2014 financial results and provide a general business update.
BMRN: 100.76 (+1.98)
After Yesterday's Decline of 1.87%, BioMarin Pharmaceutical Offers Investors Better Value
Comtex SmarTrend(R) - Mon Feb 02, 4:54PM CST
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $93.87 to a high of $97.90. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $96.38 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMRN: 100.76 (+1.98)
3 Biotech Stocks to Buy in February
Motley Fool Staff - Motley Fool - Mon Feb 02, 9:01AM CST
When it comes to figuring out the best stocks to buy in any given month or year, crystal balls can be hazy, but our top Motley Fool contributors have scoured SEC filings, read industry trade journals, and crunched numbers to uncover three biotech...
FLML: 14.15 (+0.15), BMRN: 100.76 (+1.98), RNA: 18.65 (unch), CELG: 115.88 (+0.16)
An $8 Billion Hedge Fund Bought This Extremely Risky Stock: Should You?
George Budwell, The Motley Fool - Motley Fool - Sun Feb 01, 12:02PM CST
The market activity of billionaire investors tends to attract a lot of attention because these billionaires are often perceived as having some kind of special insight into the direction of the broader market or individual stocks. In the world of...
ACAD: 34.21 (+0.37), PCYC: 163.28 (+0.23), BMRN: 100.76 (+1.98), GEVA: 99.75 (-1.68)
Prosensa Announces Intent to Voluntarily Delist From NASDAQ
GlobeNewswire - Fri Jan 30, 7:36AM CST
Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company"
, the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced today that it intends to voluntarily delist the registered shares of the Company, nominal value EUR0.01 per share (the "Shares" , from the NASDAQ Global Select Market ("NASDAQ" . Upon satisfaction of the applicable requirements for deregistration, Prosensa also intends to deregister the Shares under the Securities Exchange Act of 1934, as amended (the "Exchange Act" and to suspend its reporting obligations under the Exchange Act once it is eligible to do so. BMRN: 100.76 (+1.98), RNA: 18.65 (unch)
BioMarin Announces Final Results of Tender Offer for Prosensa's Shares and Completion of Subsequent Offering Period
GlobeNewswire - Fri Jan 30, 7:00AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the final results of, and the completion of the subsequent offering period relating to, the previously announced tender offer by its subsidiaries, BioMarin Falcons B.V. and BioMarin Giants B.V. (together, "Purchaser"
, to acquire all of the outstanding ordinary shares of Prosensa Holding N.V. (Nasdaq:RNA) at a purchase price of $17.75 per share, net to the seller in cash (the "Cash Consideration" , plus one non-transferrable contingent value right to receive cash payments of up to $4.14 per share in the aggregate upon the achievement of certain product approval milestones ("CVR" , in each case, without interest thereon and less any applicable withholding taxes. BMRN: 100.76 (+1.98), RNA: 18.65 (unch)
Synageva Starts Dosing in Phase I/II Study for Sanfilippo B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 5:25PM CST
Synageva BioPharma Corp. (GEVA) has commenced patient dosing in a phase I/II study on SBC-103 for mucopolysaccharidosis IIIB (also known as Sanfilippo B syndrome).
BMRN: 100.76 (+1.98), GEVA: 99.75 (-1.68), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
